A Study to Evaluate the Efficacy and Safety of AD-223

Addpharma

Status and phase: Completed; Phase 3

Conditions: Hypertension,Essential

Treatments: Drug: AD-223C; Drug: AD-223B Placebo; Drug: AD-223A Placebo; Drug: AD-223C Placebo; Drug: AD-223B; Drug: AD-223A

Study type: Interventional

Funder types: Industry

Identifiers

NCT06052748

AD-223P3

Details and patient eligibility

About

The purpose of this study is to evaluate the efficacy and safety of AD-223

Full description

Condition or disease : hypertension

Enrollment: 502 patients

Sex: All

Ages: 19+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Signed informed consent
• Other inclusions applied

Exclusion criteria

• Orthostatic hypotension with symptom
• Other exclusions applied

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

502 participants in 4 patient groups

Test group

Experimental group

Description:

AD-223A+AD-223B+AD-223C Placebo

Treatment:

Drug: AD-223A

Drug: AD-223B

Drug: AD-223C Placebo

Control group 1

Active Comparator group

Description:

AD-223A+AD-223B Placebo+AD-223C Placebo

Treatment:

Drug: AD-223A

Drug: AD-223C Placebo

Drug: AD-223B Placebo

Control group 2

Active Comparator group

Description:

AD-223A Placebo+AD-223B+AD-223C Placebo

Treatment:

Drug: AD-223B

Drug: AD-223C Placebo

Drug: AD-223A Placebo

Control group 3

Active Comparator group

Description:

AD-223A Placebo+AD-223B Placebo+AD-223C

Treatment:

Drug: AD-223A Placebo

Drug: AD-223B Placebo

Drug: AD-223C